David Shaw’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

David Shaw’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-489,613	Closed	-$11.8M	–	4812
2023 Q1	$11.8M	Sell	489,613 -653,687	-57%	-$8.2M	0.01%	1231
2022 Q4	$12.1M	Buy	1,143,300 +1,038,757	+994%	+$8.38M	0.01%	1285
2022 Q3	$471K	Buy	104,543 +46,400	+80%	+$211K	﹤0.01%	4073
2022 Q2	$233K	Buy	58,143 +7,361	+14%	+$34.9K	﹤0.01%	4481
2022 Q1	$372K	Buy	+50,782	New	+$304K	﹤0.01%	4539

Other funds holding PRVB

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

David Shaw's PRVB Position: Q2 2023 in Review

David Shaw sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 489,613 shares — an estimated $11.8M sold.

David Shaw first reported a position in PRVB in Q1 2022 and held it in 5 quarters. The position peaked at $12.1M in Q4 2022. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

David Shaw reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
David Shaw sold 489,613 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $11.8M.
David Shaw first reported a position in Provention Bio, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
David Shaw's Provention Bio, Inc. Common Stock position peaked at $12.1M in Q4 2022.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on D.E. Shaw & Co's 13F filing for Q2 2023, filed 14 Aug 2023.